Member Info for Parob

This has the feel that it’s about to turn soon, and the chart looks that way too. Just topped up 33.7K. I like buying the dips!

I agree Forrestdreams and we have a potentially powerful triple bottom playing out on the candlestick chart. Could be explosive once we break out of the 2.5 year downtrend, and with commercial deals mounting up we can’t be far off, hence two top ups for me today.

Good to see the newsflow picking up here. Momentum building.

Wouldn’t surprise me to see another large delayed buy appear later.

...on very low volume. Is there another large buy order being worked through in the background?

I'm sure some of the smaller institutions will start taking notice when N4 has a market cap of �50million. Once we're through 24.5p I can see this moving very swiftly indeed back to the 30p+ level.

Over the past couple of days I’ve done a few large dummy sells and most of the time was offered ABOVE the mid price. Demand has definitely returned. I have a good feeling for this coming week.

SMALL CAP MOVERS: hTTp://www.thisismoney.co.uk/money/investing/article-5586479/SMALL-CAP-MOVERS-Pebble-Beach-Systems-soars.html Another technology group, Internet of Things (IoT) firm Tern PLC (LON:TERN) also saw strong demand this week, with its shares jumping 64 per cent higher to 6.15p on news its investee company Device Authority had entered into a new partnership, with Franco-Dutch firm Gemalto. Under the agreement, the AIM-listed firm said the two companies will work to achieve interoperability of DA’s KeyScaler technology with Gemalto’s Safenet Luna Hardware Security Module in order to establish a product which helps enterprises deliver on their IoT strategies safely and in line with compliance requirements.

Is it possible that up-front payments could still be received whilst further Nuvec development work is ongoing by N4?

N4 Pharma are exhibiting at Mello2018 at the end of April: http://mello2018.com/exhibitors.html# Should drum up additional investor interest in the company.

Viagra Just Turned 20. Here's How Much Money the ED Drug Makes By SY MUKHERJEE March 27, 2018 http://fortune.com/2018/03/27/viagra-anniversary-pfizer/

Aim_Chaos tweet: Viagra is now an OTT drug in the UK. The BBC today highlights Viagra's flaws that #N4P is trying to rectify: i) an hour to take effect; ii) only 4 hour life; iii) not to be taken with big meals. N4P is ideally positioned to capitalise on the inevitable rocketing sales of Viagra.

20 years of Viagra: The little blue pill that changed the world It�s 20 years since Viagra was licensed. Suzanne Harrington looks back on the history of a drug that revolutionised many people�s sex lives https://www.irishexaminer.com/breakingnews/lifestyle/features/20-years-of-viagra-the-little-blue-pill-that-changed-the-world-833809.html

Well that dip has offered investors who missed out on the last rise an opportunity to buy in whilst the company has a low valuation. Should see more buying pressure this coming week as new investors continue to accumulate whilst those who sold out at higher levels rebuild their positions with more shares for their money.

Two page write up on N4P in AJBell/Shares mag, from page 52+ (Feb 2018): hTTps://tinyurl.com/y87scolj NT/Company presentation - Nov 2017 hTTp://www.piworld.co.uk/2017/11/11/n4-pharma-n4p-presentation-at-sharesoc-growth-seminar-november-2017/ Company presentation slides (Nov 2017) hTTps://www.n4pharma.com/sites/default/files/documents/N4Pharma_investor_presentation%20update%20nov%202017%20sharesoc.pdf “We’re not a one-trick pony” - NT Proactive interview May 2017: hTTps://tinyurl.com/l5zjp52 Nigel Theobald phone interview (May 2017) hTTp://www.share-talk.com/share-news/n4-pharma-plc-aimn4p-update-on-sildenafil-clinical-plans/ Aim_Chaos research report (July 2017) hTTps://aimchaos.files.wordpress.com/2017/07/n4p-bought-31-07-2017.pdf He subsequently wrote: (Jan 2018) “Morning all, thought I'd repost this brief note on N4P that I penned last summer, given that there's been an influx of new investors recently. aimchaos.files.wordpress.com/2017/07/n4p-bought-31-07-2017.pdf As is set out on pp.7-11, I value the reformulation side of the business at 63p in its current state (p.11 does state 73.3p, but the Paroxetine reformulation has been discontinued, and so I have subtracted the 10.4p from that). This valuation is I think incredibly conservative. As I explain in the note, novel drugs have a 5-10% success rate from pre-clinical to commercialisation. Reformulated drugs have a success rate many multiples of this, yet I have factored in only 5-10% rates in my calculations. Moreover, I have not attempted to calculate a valuation for Nuvec. I am of the opinion however that it could eventually dwarf the reformulation division in value. Holding 4,000,000 for the long term.”

Hopefully we’ve seen the final capitulation that I mentioned this morning. If so, we could be looking at a strong recovery next week.

Final capitulation before the rebound?

What will happen to the share price should the human trials be successful?

VERY EXCITING! Our SlimBiome has been shortlisted among the finalist at the NutraIngredients Awards "Ingredient of the Year: Weight Management" presented at VitaFoods in Geneva in May. #Health #microbiome The leading European show for the Supplement and Nutraceutical industry !

Per tweet just now: VERY EXCITING ! Our LPLDL has been shortlisted among the finalist at the NutraIngredients Awards "Probiotic Product of the Year" presented at VitaFoods in Geneva in May. #probiotics #Health #microbiome The leading European show for the Supplement and Nutraceutical industry !!